Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Capital Expenditures for 7 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 6792.11% year-over-year to $2.6 million; the trailing twelve-month figure through Jun 2026 stood at $4.6 million (down 87.5% YoY), and the FY2025 full-year result was $7.7 million, down 87.74% from the prior year.
• Capital Expenditures improved to $2.6 million in Q2 2026 per DNA's latest filing, from $1.9 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $27.0 million in Q2 2024 and bottomed at $5000.0 in Q4 2025.
• Historically, Capital Expenditures has averaged $9.9 million across 5 years, with a median of $7.6 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures tumbled 99.96% in 2025, then surged 6792.11% in 2026.
• Over 5 years, Capital Expenditures stood at $25.6 million in 2022, then tumbled by 86.56% to $3.4 million in 2023, then surged by 297.85% to $13.7 million in 2024, then sank by 99.96% to $5000.0 in 2025, then soared by 52280.0% to $2.6 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $2.6 million, $1.9 million, and $5000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.